Document is current
Any future updates will be listed below
-
Authors
Huang, Hsiao-Ching
Smart, Mary H.
Zolekar, Ashwini
Deng, Huiwen
Hubbard, Colin C.
Hoskins, Kent F.
Ko, Naomi Y.
Guadamuz, Jenny S.
Calip, Gregory S. https://orcid.org/0000-0002-7744-3518
-
Funding
Funding for this research was provided by:
National Cancer Institute (U54CA202995, U54CA202997, U54CA203000)
National Center for Advancing Translational Sciences (KL2TR002002)
- License Information
-
More Information
Article History
Received: 19 October 2021
Accepted: 6 April 2022
First Online: 23 April 2022
Declarations
:
: Financial interests: Hsiao-Ching Huang is supported by the UIC/AbbVie Fellowship in Pharmacovigilance and patient safety. Huiwen Deng is supported by the UIC/AbbVie Fellowship in Health Economics and Outcomes Research. Colin C. Hubbard reports funding from Pfizer. Kent F Hoskins reports funding from Pfizer, Inc. Naomi Y Ko reports funding and advisory from Pfizer, Inc. Gregory S. Calip reports current employment with Flatiron Health, stock ownership in Roche and research grants from Pfizer unrelated to this study.The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders. Non-financial interests: None.
